Showing results (61-70 of 89) with videos related to
Sort By:
Pageof 9
Translational Andrology and Urology|May 10, 2021
MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancerKyosuke Matsuzaki, Kazutoshi Fujita, Eisuke Tomiyama, et al.Cancer Science|October 7, 2020
Fragmentation of cell-free DNA is induced by upper-tract urothelial carcinoma-associated systemic inflammationKosuke Nakano, Yoshiyuki Yamamoto, Gaku Yamamichi, et al.Oncology Reports|November 29, 2018
Leukocyte‑associated immunoglobulin‑like receptor 1 promotes tumorigenesis in RCCKentaro Jingushi, Motohide Uemura, Kosuke Nakano, et al.International Journal of Radiation Oncology, Biology, Physics|August 5, 2015
High-Dose-Rate Brachytherapy as Monotherapy for Intermediate- and High-Risk Prostate Cancer: Clinical Results for a Median 8-Year Follow-UpYasuo Yoshioka, Osamu Suzuki, Fumiaki Isohashi, et al.Biochemical and Biophysical Research Communications|January 17, 2020
The role of actinin-4 (ACTN4) in exosomes as a potential novel therapeutic target in castration-resistant prostate cancerYu Ishizuya, Motohide Uemura, Ryohei Narumi, et al.Cancer Science|January 25, 2020
MicroRNA-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinomaCong Wang, Motohide Uemura, Eisuke Tomiyama, et al.International Journal of Clinical Oncology|January 20, 2021
The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective studyTaigo Kato, Akira Nagahara, Norihiko Kawamura, et al.Frontiers in Oncology|June 9, 2020
Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder CancerYujiro Hayashi, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|February 20, 2022
Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinomaYoko Koh, Kosuke Nakano, Kotoe Katayama, et al.Anticancer Research|November 4, 2021
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell CarcinomaTaigo Kato, Akira Nagahara, Norihiko Kawamura, et al.Pageof 9